Cure Glomerulonephropathy Network: CureGN
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 22-006717
About this study
The purpose of this study is to maintain and support the infrastructure for the CureGN Consortium and its ancillary study program to perform patient-relevant research.
Additionally, to implement efficient study administration procedures to accomplish the consortium goals, and engage patients as partners in research
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Diagnosis of MCD, FSGS, MN, or IgAN on first diagnostic kidney biopsy, as per specified pathology definitions.
- First diagnostic kidney biopsy within 5 years of study enrollment.
- Access to first kidney biopsy report and/or slides.
- All ages.
- Willingness to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site.
- Informed consent and, where age appropriate, informed assent.
Exclusion Criteria:
- ESKD, defined as chronic dialysis or kidney transplant.
- Institutionalized patient.
- Solid organ or bone marrow transplant recipient at time of first kidney biopsy.
- Diagnosis of any of the following at the time of first diagnostic kidney biopsy:
- Diabetes mellitus (except gestational or diet controlled);
- Histopathologic findings of diabetic glomerulosclerosis;
- Systemic lupus erythematosus;
- HIV infection;
- Active malignancy, except for non-melanoma skin cancer;
- Active Hepatitis B or C infection, defined as positive viral load.
Eligibility last updated 6/24/22. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Carl Cramer, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available